NRx Pharmaceuticals, Inc.
NRXP
$2.27
-$0.02-0.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.66% | 43.48% | 36.49% | 31.35% | 24.16% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 25.00% | 25.00% | 25.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 362.15% | -85.58% | -60.77% | -46.24% | 572.16% |
| Change in Net Operating Assets | 2.46% | 128.58% | 77.10% | 721.18% | 638.77% |
| Cash from Operations | 50.88% | 56.20% | 50.89% | 45.75% | 45.52% |
| Capital Expenditure | -- | 133.33% | 83.33% | 109.09% | 70.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 133.33% | 83.33% | 109.09% | 70.00% |
| Total Debt Issued | 650.69% | -71.33% | -98.55% | -90.59% | -90.59% |
| Total Debt Repaid | -112.52% | -119.88% | -6,678.89% | -1,094.98% | -678.96% |
| Issuance of Common Stock | -27.22% | -28.13% | -30.79% | 207.03% | -64.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 20.71% | -74.34% | -95.14% | -65.61% | -80.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.61% | 22.37% | -36.45% | 35.91% | -104.73% |